{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T05:38:49Z","timestamp":1759815529365},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T00:00:00Z","timestamp":1588204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40272-020-00394-3","type":"journal-article","created":{"date-parts":[[2020,4,30]],"date-time":"2020-04-30T01:02:32Z","timestamp":1588208552000},"page":"311-319","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The Use of TNF\u03b1 Inhibitors in Treating Pediatric Skin Disorders"],"prefix":"10.1007","volume":"22","author":[{"given":"Quoc-Bao D.","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline T.","family":"Starling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adelaide A.","family":"Hebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,4,30]]},"reference":[{"issue":"4","key":"394_CR1","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1073\/pnas.61.4.1250","volume":"61","author":"WP Kolb","year":"1968","unstructured":"Kolb WP, Granger GA. Lymphocyte in vitro cytotoxicity: characterization of human lymphotoxin. Proc Natl Acad Sci USA. 1968;61(4):1250\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"9","key":"394_CR2","doi-asserted-by":"publisher","first-page":"3666","DOI":"10.1073\/pnas.72.9.3666","volume":"72","author":"EA Carswell","year":"1975","unstructured":"Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975;72(9):3666\u2013700.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"2","key":"394_CR3","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1186\/ar4541","volume":"16","author":"DS Pisetsky","year":"2014","unstructured":"Pisetsky DS. Tumor necrosis factor: is it time to change the name? Arthritis Res Ther. 2014;16(2):108.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"394_CR4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/intimm\/dxu102","volume":"27","author":"C Monaco","year":"2015","unstructured":"Monaco C, Nanchahal J, Taylor P, Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol. 2015;27(1):55\u201362.","journal-title":"Int Immunol"},{"issue":"12","key":"394_CR5","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.1002\/art.1780361206","volume":"36","author":"MJ Elliott","year":"1993","unstructured":"Elliott MJ, Maini RN, Feldmann M, Long-Fox A, Charles P, Katsikis P, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. 1993;36(12):1681\u201390.","journal-title":"Arthritis Rheum"},{"key":"394_CR6","first-page":"95","volume":"87","author":"C Beylot","year":"1979","unstructured":"Beylot C, Puissant A, Bioulac P, Saurat JH, Pringuet R, Doutre MS. Particular clinical features of psoriasis in infants and chidren. Acta Derm Venereol Suppl (Stockh). 1979;87:95\u20137.","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"5","key":"394_CR7","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1111\/j.1396-0296.2004.04039.x","volume":"17","author":"D Lewkowicz","year":"2004","unstructured":"Lewkowicz D, Gottlieb AB. Pediatric psoriasis and psoriatic arthritis. Dermatol Ther. 2004;17(5):364\u201375.","journal-title":"Dermatol Ther"},{"issue":"3","key":"394_CR8","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1056\/NEJMoa066886","volume":"358","author":"AS Paller","year":"2008","unstructured":"Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, et al. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med. 2008;358(3):241\u201351.","journal-title":"N Engl J Med"},{"issue":"2","key":"394_CR9","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.jaad.2015.09.056","volume":"74","author":"AS Paller","year":"2016","unstructured":"Paller AS, Siegfried EC, Pariser DM, Rice KC, Trivedi M, Iles J, et al. Long-term safety and efficacy of etanercept in children and adolescents with plaque psoriasis. J Am Acad Dermatol. 2016;74(2):280\u2013287.e3.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"394_CR10","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/jcph.1029","volume":"58","author":"RG Langley","year":"2018","unstructured":"Langley RG, Kasichayanula S, Trivedi M, Aras GA, Kaliyaperumal A, Yuraszeck T, et al. Pharmacokinetics, immunogenicity, and efficacy of etanercept in pediatric patients with moderate to severe plaque psoriasis. J Clin Pharmacol. 2018;58(3):340\u20136.","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"394_CR11","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1001\/jamadermatol.2017.3029","volume":"153","author":"IMGJ Bronckers","year":"2017","unstructured":"Bronckers IMGJ, Seyger MMB, West DP, Lara-Corrales I, Tollefson M, Tom WL, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147\u201357.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"394_CR12","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/09546634.2017.1364692","volume":"29","author":"VD Lernia","year":"2018","unstructured":"Lernia VD, Guarneri C, Stingeni L, Gisondi P, Bonamonte D, Pinton PGC, et al. Effectiveness of etanercept in children with plaque psoriasis in real practice: a one-year multicenter retrospective study. J Dermatol Treat. 2018;29(3):217\u20139.","journal-title":"J Dermatol Treat"},{"issue":"10089","key":"394_CR13","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/S0140-6736(17)31189-3","volume":"390","author":"K Papp","year":"2017","unstructured":"Papp K, Tha\u00e7i D, Marcoux D, Weibel L, Philipp S, Ghislain P-D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40\u20139.","journal-title":"Lancet"},{"issue":"11","key":"394_CR14","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1111\/jdv.13388","volume":"30","author":"V Tsang","year":"2016","unstructured":"Tsang V, Dvorakova V, Enright F, Murphy M, Gleeson C. Successful use of infliximab as first line treatment for severe childhood generalized pustular psoriasis. J Eur Acad Dermatol Venereol JEADV. 2016;30(11):e117\u2013e11919.","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"issue":"2","key":"394_CR15","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.jaad.2018.04.013","volume":"79","author":"M Lebwohl","year":"2018","unstructured":"Lebwohl M, Blauvelt A, Paul C, Sofen H, W\u0119g\u0142owska J, Piguet V, et al. Certolizumab pegol for the treatment of chronic plaque psoriasis: results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT). J Am Acad Dermatol. 2018;79(2):266\u2013276.e5.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"394_CR16","doi-asserted-by":"publisher","first-page":"446","DOI":"10.5021\/ad.2015.27.4.446","volume":"27","author":"W-K Lee","year":"2015","unstructured":"Lee W-K, Kim G-W, Cho H-H, Kim W-J, Mun J-H, Song M, et al. Erythrodermic psoriasis treated with golimumab: a case report. Ann Dermatol. 2015;27(4):446\u20139.","journal-title":"Ann Dermatol"},{"issue":"3","key":"394_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1111\/pde.13081","volume":"34","author":"JB Eickstaedt","year":"2017","unstructured":"Eickstaedt JB, Killpack L, Tung J, Davis D, Hand JL, Tollefson MM. Psoriasis and psoriasiform eruptions in pediatric patients with inflammatory bowel disease treated with anti-tumor necrosis factor alpha agents. Pediatr Dermatol. 2017;34(3):253\u201360.","journal-title":"Pediatr Dermatol"},{"key":"394_CR18","doi-asserted-by":"crossref","unstructured":"de Vasconcellos JB, Pereira D do N, Vargas TJ de S, Levy RA, Pinheiro G da RC, Cursi \u00cdB (2016) Paradoxical psoriasis after the use of anti-TNF in a patient with rheumatoid arthritis. An Bras Dermatol 91(5 Suppl 1):137\u20139.","DOI":"10.1590\/abd1806-4841.20164456"},{"issue":"2","key":"394_CR19","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1056\/NEJMcp1014163","volume":"366","author":"GBE Jemec","year":"2012","unstructured":"Jemec GBE. Hidradenitis Suppurativa. N Engl J Med. 2012;366(2):158\u201364.","journal-title":"N Engl J Med"},{"issue":"4","key":"394_CR20","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.jaad.2008.11.911","volume":"60","author":"A Alikhan","year":"2009","unstructured":"Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol. 2009;60(4):539\u201361.","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"394_CR21","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1111\/j.1600-0625.2012.01552.x","volume":"21","author":"HH van der Zee","year":"2012","unstructured":"van der Zee HH, Laman JD, Boer J, Prens EP. Hidradenitis suppurativa: viewpoint on clinical phenotyping, pathogenesis and novel treatments. Exp Dermatol. 2012;21(10):735\u20139.","journal-title":"Exp Dermatol"},{"issue":"3","key":"394_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.jaad.2012.07.027","volume":"68","author":"I Cosmatos","year":"2013","unstructured":"Cosmatos I, Matcho A, Weinstein R, Montgomery MO, Stang P. Analysis of patient claims data to determine the prevalence of hidradenitis suppurativa in the United States. J Am Acad Dermatol. 2013;68(3):412\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"394_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jaad.2008.06.020","volume":"59","author":"JE Revuz","year":"2008","unstructured":"Revuz JE, Canoui-Poitrine F, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Prevalence and factors associated with hidradenitis suppurativa: results from two case-control studies. J Am Acad Dermatol. 2008;59(4):596\u2013601.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"394_CR24","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1016\/j.jaad.2009.09.021","volume":"62","author":"\u0141 Matusiak","year":"2010","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski JC. Hidradenitis suppurativa markedly decreases quality of life and professional activity. J Am Acad Dermatol. 2010;62(4):706\u2013708.e1.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"394_CR25","doi-asserted-by":"publisher","first-page":"264","DOI":"10.2340\/00015555-0866","volume":"90","author":"\u0141 Matusiak","year":"2010","unstructured":"Matusiak \u0141, Bieniek A, Szepietowski J. Psychophysical aspects of Hidradenitis Suppurativa. Acta Derm Venereol. 2010;90(3):264\u20138.","journal-title":"Acta Derm Venereol"},{"key":"394_CR26","doi-asserted-by":"crossref","unstructured":"Sabat R, Chanwangpong A, Schneider-Burrus S, Metternich D, Kokolakis G, Kurek A, et al. Increased prevalence of metabolic syndrome in Patients with Acne Inversa. Bruggemann H, editor. PLoS One. 2012 7(2):e31810","DOI":"10.1371\/journal.pone.0031810"},{"issue":"8","key":"394_CR27","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1001\/jamadermatol.2017.0201","volume":"153","author":"A Garg","year":"2017","unstructured":"Garg A, Kirby JS, Lavian J, Lin G, Strunk A. Sex- and age-adjusted population analysis of prevalence estimates for Hidradenitis Suppurativa in the United States. JAMA Dermatol. 2017;153(8):760\u20134.","journal-title":"JAMA Dermatol"},{"issue":"6","key":"394_CR28","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1111\/j.1365-2133.2011.10254.x","volume":"164","author":"HH van der Zee","year":"2011","unstructured":"van der Zee HH, de Ruiter L, van den Broecke DG, Dik WA, Laman JD, Prens EP. Elevated levels of tumour necrosis factor (TNF)-\u03b1, interleukin (IL)-1\u03b2 and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-\u03b1 and IL-1\u03b2. Br J Dermatol. 2011;164(6):1292\u20138.","journal-title":"Br J Dermatol"},{"issue":"5","key":"394_CR29","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, et al. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. N Engl J Med. 2016;375(5):422\u201334.","journal-title":"N Engl J Med"},{"issue":"6","key":"394_CR30","first-page":"AB33","volume":"76","author":"C Zouboulis","year":"2016","unstructured":"Zouboulis C, Okun MM, Gniadecki R, Foley PA, Lynde C, Weisman J, Williams DA. Adalimumab efficacy in hidradenitis suppurativa patients is sustained at least three years with weekly dosing: results from a phase 3 open-label extension study (PIONEER). J Am Acad Dermatol. 2017;76(6):AB33.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"394_CR31","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jaad.2018.05.040","volume":"80","author":"CC Zouboulis","year":"2019","unstructured":"Zouboulis CC, Okun MM, Prens EP, Gniadecki R, Foley PA, Lynde C, et al. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa\/acne inversa: 3-year results of a phase 3 open-label extension study. J Am Acad Dermatol. 2019;80(1):60\u201369.e2.","journal-title":"J Am Acad Dermatol"},{"key":"394_CR32","unstructured":"European Public Assessment Report. Humira [Internet]. European Medicines Agency. 2018 [cited 2019 Jul 22]. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/humira"},{"issue":"5","key":"394_CR33","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1001\/archdermatol.2009.49","volume":"145","author":"R Blanco","year":"2009","unstructured":"Blanco R, Mart\u00ednez-Taboada VM, Villa I, Gonz\u00e1lez-Vela MC, Fern\u00e1ndez-Llaca H, Agudo M, et al. Long-term successful adalimumab therapy in severe Hidradenitis Suppurativa. Arch Dermatol. 2009;145(5):580\u20134.","journal-title":"Arch Dermatol"},{"issue":"4","key":"394_CR34","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1365-2133.2005.07067.x","volume":"154","author":"C Cusack","year":"2006","unstructured":"Cusack C, Buckley C. Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol. 2006;154(4):726\u20139.","journal-title":"Br J Dermatol"},{"issue":"2","key":"394_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jaad.2009.06.050","volume":"62","author":"A Grant","year":"2010","unstructured":"Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol. 2010;62(2):205\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"394_CR36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/jid.2010.251","volume":"131","author":"TE Shaw","year":"2011","unstructured":"Shaw TE, Currie GP, Koudelka CW, Simpson EL. Eczema prevalence in the United States: data from the 2003 National Survey of Children\u2019s Health. J Invest Dermatol. 2011;131(1):67\u201373.","journal-title":"J Invest Dermatol"},{"issue":"9","key":"394_CR37","first-page":"873","volume":"8","author":"P Rullan","year":"2009","unstructured":"Rullan P, Murase J. Two cases of chronic atopic dermatitis treated with soluble tumor necrosis factor receptor therapy. J Drugs Dermatol JDD. 2009;8(9):873\u20136.","journal-title":"J Drugs Dermatol JDD"},{"issue":"2","key":"394_CR38","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1016\/j.jaad.2005.03.013","volume":"53","author":"RL Buka","year":"2005","unstructured":"Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol. 2005;53(2):358\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"4 Pt 1","key":"394_CR39","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/S0151-9638(07)89187-3","volume":"134","author":"D Lebas","year":"2007","unstructured":"Lebas D, Staumont-Sall\u00e9 D, Solau-Gervais E, Flipo R-M, Delaporte E. Cutaneous manifestations during treatment with TNF-alpha blockers: 11 cases. Ann Dermatol Venereol. 2007;134(4 Pt 1):337\u201342.","journal-title":"Ann Dermatol Venereol"},{"issue":"11","key":"394_CR40","first-page":"2506","volume":"30","author":"H Mangge","year":"2003","unstructured":"Mangge H, Gindl S, Kenzian H, Schauenstein K. Atopic dermatitis as a side effect of anti-tumor necrosis factor-alpha therapy. J Rheumatol. 2003;30(11):2506\u20137.","journal-title":"J Rheumatol"},{"issue":"8","key":"394_CR41","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ad.2011.11.013","volume":"103","author":"R Ruiz-Villaverde","year":"2012","unstructured":"Ruiz-Villaverde R, Gal\u00e1n-Gutierrez M. Exacerbation of atopic dermatitis in a patient treated with infliximab. Actas Dermosifiliogr. 2012;103(8):743\u20136.","journal-title":"Actas Dermosifiliogr"},{"issue":"10","key":"394_CR42","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s40265-017-0768-3","volume":"77","author":"M Shirley","year":"2017","unstructured":"Shirley M. Dupilumab: first global approval. Drugs. 2017;77(10):1115\u201321.","journal-title":"Drugs"},{"issue":"1","key":"394_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/pde.13697","volume":"36","author":"AD Treister","year":"2019","unstructured":"Treister AD, Lio PA. Long-term off-label dupilumab in pediatric atopic dermatitis: a case series. Pediatr Dermatol. 2019;36(1):85\u20138.","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"394_CR44","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/archderm.1984.01650420067018","volume":"120","author":"FC Powell","year":"1984","unstructured":"Powell FC, Perry HO. Pyoderma gangrenosum in childhood. Arch Dermatol. 1984;120(6):757\u201361.","journal-title":"Arch Dermatol"},{"issue":"5","key":"394_CR45","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1097\/00005176-200205000-00016","volume":"34","author":"LA Batres","year":"2002","unstructured":"Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr. 2002 34(5):558\u201360.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"394_CR46","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1097\/00005176-200308000-00013","volume":"37","author":"S Kugathasan","year":"2003","unstructured":"Kugathasan S, Miranda A, Nocton J, Drolet BA, Raasch C, Binion DG. Dermatologic manifestations of crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr. 2003;37(2):150.","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"394_CR47","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/gut.2005.074815","volume":"55","author":"TN Brooklyn","year":"2006","unstructured":"Brooklyn TN, Dunnill MGS, Shetty A, Bowden JJ, Williams JDL, Griffiths CEM, et al. Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut. 2006;55(4):505\u20139.","journal-title":"Gut"},{"issue":"5","key":"394_CR48","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1001\/archsurg.135.5.564","volume":"135","author":"DG Sheldon","year":"2000","unstructured":"Sheldon DG, Sawchuk LL, Kozarek RA, Thirlby RC. Twenty cases of peristomal Pyoderma Gangrenosum. Arch Surg. 2000;135(5):564.","journal-title":"Arch Surg"},{"issue":"7","key":"394_CR49","first-page":"930","volume":"137","author":"MH Tan","year":"2001","unstructured":"Tan MH, Gordon M, Lebwohl O, George J, Lebwohl MG. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol. 2001 137(7):930\u20133.","journal-title":"Arch Dermatol"},{"issue":"9","key":"394_CR50","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1080\/003655202320378338","volume":"37","author":"T Ljung","year":"2002","unstructured":"Ljung T, Staun M, Grove O, Fausa O, Vatn MH, Hellstr\u00f6m PM. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol. 2002 37(9):1108\u201310.","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"394_CR51","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1080\/gas.37.7.863.865","volume":"37","author":"JK Triantafillidis","year":"2002","unstructured":"Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol. 2002 37(7):863\u20135.","journal-title":"Scand J Gastroenterol"},{"key":"394_CR52","unstructured":"Arnott IDR, Mcdonald D, Williams A, Ghosh S. Clinical use of Infliximab in Crohn\u2019s disease: the Edinburgh experience."},{"issue":"3","key":"394_CR53","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1159\/000065860","volume":"205","author":"F Grange","year":"2002","unstructured":"Grange F, Djilali-Bouzina F, Weiss AM, Polette A, Guillaume JC. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn\u2019s disease: rapid cure with infliximab. Dermatol Basel Switz. 2002;205(3):278\u201380.","journal-title":"Dermatol Basel Switz"},{"issue":"5","key":"394_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/ijd.13584","volume":"56","author":"E Kechichian","year":"2017","unstructured":"Kechichian E, Haber R, Mourad N, El Khoury R, Jabbour S, Tomb R. Pediatric pyoderma gangrenosum: a systematic review and update. Int J Dermatol. 2017;56(5):486\u201395.","journal-title":"Int J Dermatol"},{"issue":"2","key":"394_CR55","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/j.1365-4632.2008.03412.x","volume":"47","author":"SE Jacob","year":"2008","unstructured":"Jacob SE, Weisman RS, Kerdel FA. Pyoderma gangrenosum\u2014rebel without a cure? Int J Dermatol. 2008;47(2):192\u20134.","journal-title":"Int J Dermatol"},{"issue":"6","key":"394_CR56","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1111\/j.1365-2133.2007.08212.x","volume":"157","author":"RG Pomerantz","year":"2007","unstructured":"Pomerantz RG, Husni ME, Mody E, Qureshi AA. Adalimumab for treatment of pyoderma gangrenosum. Br J Dermatol. 2007;157(6):1274\u20135.","journal-title":"Br J Dermatol"},{"issue":"4","key":"394_CR57","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.sder.2006.08.006","volume":"25","author":"MJOJ Kerns","year":"2006","unstructured":"Kerns MJoJ, Graves JE, Smith DI, Heffernan MP, Off-label uses of biologic agents in dermatology: a 2006 update. Semin Cutan Med Surg. 2006;25(4):226\u201340.","journal-title":"Semin Cutan Med Surg."},{"issue":"3","key":"394_CR58","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1016\/j.jaad.2005.10.058","volume":"54","author":"DB Roy","year":"2006","unstructured":"Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. J Am Acad Dermatol. 2006 54(3):S128\u2013S134134.","journal-title":"J Am Acad Dermatol"},{"key":"394_CR59","unstructured":"Pyoderma gangrenosum treated with anti\u2010TNF alpha therapy (etanercept) - Pastor - 2006 - Clinical and Experimental Dermatology - Wiley Online Library [Internet]. [cited 2020 Jan 11]. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.1365-2230.2005.01972.x"},{"issue":"5\u20136","key":"394_CR60","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1080\/09546630500424722","volume":"16","author":"G Goldenberg","year":"2005","unstructured":"Goldenberg G, Jorizzo JL. Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat. 2005;16(5\u20136):347\u20139.","journal-title":"J Dermatol Treat"},{"issue":"10","key":"394_CR61","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1111\/j.1365-4632.2007.03286.x","volume":"46","author":"CA Charles","year":"2007","unstructured":"Charles CA, Leon A, Banta MR, Kirsner RS. Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol. 2007;46(10):1095\u20139.","journal-title":"Int J Dermatol"},{"issue":"5","key":"394_CR62","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/j.jaad.2016.12.024","volume":"76","author":"DY Hsu","year":"2017","unstructured":"Hsu DY, Brieva J, Silverberg NB, Paller AS, Silverberg JI. Pediatric Stevens-Johnson syndrome and toxic epidermal necrolysis in the United States. J Am Acad Dermatol. 2017;76(5):811\u2013817.e4.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"394_CR63","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1080\/09546634.2019.1577548","volume":"31","author":"S Zhang","year":"2020","unstructured":"Zhang S, Tang S, Li S, Pan Y, Ding Y. Biologic TNF-alpha inhibitors in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a systemic review. J Dermatol Treat. 2020 31(1):66\u201373.","journal-title":"J Dermatol Treat"},{"issue":"3","key":"394_CR64","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","volume":"128","author":"C-W Wang","year":"2018","unstructured":"Wang C-W, Yang L-Y, Chen C-B, Ho H-C, Hung S-I, Yang C-H, et al. Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions. J Clin Invest. 2018;128(3):985\u201396.","journal-title":"J Clin Invest"},{"issue":"1","key":"394_CR65","first-page":"E15","volume":"101","author":"KF Wooldridge","year":"2018","unstructured":"Wooldridge KF, Boler PL, Lee BD. Tumor necrosis factor \u03b1 inhibitors in the treatment of toxic epidermal necrolysis. Cutis. 2018;101(1):E15\u2013E21.","journal-title":"Cutis"},{"issue":"4","key":"394_CR66","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1111\/pde.12029","volume":"31","author":"V Scott-Lang","year":"2014","unstructured":"Scott-Lang V, Tidman M, McKay D. Toxic epidermal necrolysis in a child successfully treated with infliximab. Pediatr Dermatol. 2014;31(4):532\u20134.","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"394_CR67","first-page":"61","volume":"23","author":"LC Zarate-Correa","year":"2013","unstructured":"Zarate-Correa LC, Carrillo-Gomez DC, Ramirez-Escobar AF, Serrano-Reyes C. Toxic epidermal necrolysis successfully treated with infliximab. J Investig Allergol Clin Immunol. 2013;23(1):61\u20133.","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"4","key":"394_CR68","doi-asserted-by":"crossref","first-page":"420","DOI":"10.2340\/00015555-0462","volume":"88","author":"A Wojtkiewicz","year":"2008","unstructured":"Wojtkiewicz A, Wysocki M, Fortuna J, Chrupek M, Matczuk M, Koltan A, Wojtkiewicz A, Wysocki M, Fortuna J, et al. Beneficial and rapid effect of infliximab on the course of toxic epidermal necrolysis. Acta Derm Venereol. 2008;88(4):420\u20131.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"394_CR69","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1111\/pde.13778","volume":"36","author":"L Chafranska","year":"2019","unstructured":"Chafranska L, Saunte DM, Behrendt N, Nygaard U, Christensen RJ, Sand C, et al. Pediatric toxic epidermal necrolysis treated successfully with infliximab. Pediatr Dermatol. 2019;36(3):342\u20135.","journal-title":"Pediatr Dermatol"},{"issue":"5","key":"394_CR70","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1177\/1203475418758989","volume":"22","author":"GM Gavigan","year":"2018","unstructured":"Gavigan GM, Kanigsberg ND, Ramien ML. Pediatric Stevens-johnson syndrome\/toxic epidermal necrolysis halted by etanercept. J Cutan Med Surg. 2018;22(5):514\u20135.","journal-title":"J Cutan Med Surg"},{"issue":"8","key":"394_CR71","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1016\/j.burns.2014.01.027","volume":"40","author":"P Paquet","year":"2014","unstructured":"Paquet P, Jennes S, Rousseau AF, Libon F, Delvenne P, Pi\u00e9rard GE. Effect of N-acetylcysteine combined with infliximab on toxic epidermal necrolysis. A proof-of-concept study. Burns J Int Soc Burn Inj. 2014;40(8):1707\u201312.","journal-title":"Burns J Int Soc Burn Inj."},{"issue":"9433","key":"394_CR72","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S0140-6736(04)16814-1","volume":"364","author":"JC Burns","year":"2004","unstructured":"Burns JC, Glod\u00e9 MP. Kawasaki syndrome. Lancet. 2004 364(9433):533\u201344.","journal-title":"Lancet"},{"key":"394_CR73","first-page":"012448","volume":"8","author":"N Yamaji","year":"2019","unstructured":"Yamaji N, da Silva LK, Shoda T, Ishitsuka K, Kobayashi T, Ota E, et al. TNF-\u03b1 blockers for the treatment of Kawasaki disease in children. Cochrane Database Syst Rev. 2019;8:012448.","journal-title":"Cochrane Database Syst Rev."},{"issue":"1","key":"394_CR74","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.jaad.2007.09.018","volume":"58","author":"AA Nelson","year":"2008","unstructured":"Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 58(1):125\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"394_CR75","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s40801-016-0093-2","volume":"3","author":"T Gu","year":"2016","unstructured":"Gu T, Shah N, Deshpande G, Tang DH, Eisenberg DF. Comparing biologic cost per treated patient across indications among adult US Managed care patients: a retrospective cohort study. Drugs Real World Outcomes. 2016 3(4):369\u201381.","journal-title":"Drugs Real World Outcomes"},{"issue":"5","key":"394_CR76","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1001\/jamainternmed.2018.7656","volume":"179","author":"A San-Juan-Rodriguez","year":"2019","unstructured":"San-Juan-Rodriguez A, Prokopovich MV, Shrank WH, Good CB, Hernandez I. Assessment of price changes of existing tumor necrosis factor inhibitors after the market entry of competitors. JAMA Intern Med. 2019;179(5):713\u20136.","journal-title":"JAMA Intern Med"},{"issue":"64","key":"394_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3310\/hta21640","volume":"21","author":"A Duarte","year":"2017","unstructured":"Duarte A, Mebrahtu T, Goncalves PS, Harden M, Murphy R, Palmer S, et al. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technol Assess Winch Engl. 2017;21(64):1\u2013244.","journal-title":"Health Technol Assess Winch Engl"},{"issue":"5","key":"394_CR78","doi-asserted-by":"publisher","first-page":"384","DOI":"10.5114\/pdia.2014.44026","volume":"32","author":"M Mazur","year":"2015","unstructured":"Mazur M, Olek-Hrab K, Karczewski J, Teresiak-Miko\u0142ajczak E, Adamski Z. Biosimilars in dermatology. Adv Dermatol Allergol Dermatol Alergol. 2015;32(5):384\u20137.","journal-title":"Adv Dermatol Allergol Dermatol Alergol"},{"issue":"2","key":"394_CR79","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s13555-018-0230-9","volume":"8","author":"J-M Carrascosa","year":"2018","unstructured":"Carrascosa J-M, Jacobs I, Petersel D, Strohal R. Biosimilar Drugs for psoriasis: principles, present, and near future. Dermatol Ther. 2018;8(2):173\u201394.","journal-title":"Dermatol Ther"},{"key":"394_CR80","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09546634.2019.1610553","volume":"16","author":"J Barker","year":"2019","unstructured":"Barker J, Girolomoni G, Egeberg A, Goncalves J, Pieper B, Kang T. Anti-TNF biosimilars in psoriasis: from scientific evidence to real-world experience. J Dermatol Treat. 2019;16:1\u20137.","journal-title":"J Dermatol Treat"},{"issue":"10","key":"394_CR81","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1080\/14712598.2019.1636963","volume":"19","author":"L Puig","year":"2019","unstructured":"Puig L, L\u00f3pez-Ferrer A. Biosimilars for the treatment of psoriasis. Expert Opin Biol Ther. 2019;19(10):993\u20131000.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"394_CR82","doi-asserted-by":"publisher","first-page":"e20183675","DOI":"10.1542\/peds.2018-3675","volume":"143","author":"MA Portman","year":"2019","unstructured":"Portman MA, Dahdah NS, Slee A, Olson AK, Choueiter NF, Soriano BD, et al. Etanercept with IVIg for acute Kawasaki disease: a randomized controlled trial. Pediatrics. 2019;143(6):e20183675. https:\/\/doi.org\/10.1542\/peds.2018-3675.","journal-title":"Pediatrics"},{"issue":"6","key":"394_CR83","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jpeds.2008.06.011","volume":"153","author":"JC Burns","year":"2008","unstructured":"Burns JC, Best BM, Mejias A, Mahony L, Fixler DE, Jafri HS, et al. Infliximab treatment of intravenous immunoglobulin-resistant Kawasaki disease. J Pediatr. 2008;153(6):833\u20138.","journal-title":"J Pediatr"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-020-00394-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-020-00394-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T13:25:44Z","timestamp":1696080344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-020-00394-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,30]]},"references-count":83,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["394"],"URL":"https:\/\/doi.org\/10.1007\/s40272-020-00394-3","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,30]]},"assertion":[{"value":"30 April 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"No sources of funding were used to support the writing of this review.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Authors Quoc-Bao D. Nguyen, MD, Caroline T. Starling, BS, and Adelaide Hebert, MD contributed to this original review article and \u00a0QB Nguyen and CT Starling\u00a0report no conflicts of interest.\u00a0Dr. Hebert's conflicts of interest: research funds paid to the UTHealth McGovern Medical School, Houston: Amgen, Sienna, Symbio,\u00a0GSK, Mayne, Promius Pharma, Ortho Dermatologics, Galderma, Leo. Dr. Hebert honoraria: Ortho Dermatologics, Amgen, Promius, Galderma, Leo; DSMB: GSK, Ortho Dermatologics.\u00a0\u00a0","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}